



**Prof. Dr. Alex Straumann**

**Contact**

Prof. Dr. Alex Straumann  
Switzerland

## Publications (8)

Biedermann L, Franke A, Seibold F, Quattropani C, Straumann A, Schoepfer A, Hruz P. Eosinophile Ösophagitis. *Swiss Medical Forum* 2022; 22(49-50):800-804.

Schoepfer A, Henchoz S, Biedermann L, Schreiner P, Greuter T, Reinhard A, Senn J, Franke A, Burri E, Juillerat P, Simon H, Straumann A, Safroneeva E, Godat S. Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. *Gastrointest Endosc* 2021; 94:912-919.e2.

van de Veen W, Huntjens D, Wallimann A, Fonseca Guevara R, Spits H, Desislava I, Chang Y, Fassnacht C, Guenova E, Flatz L, Akdis C, van Splunter M, Stanić B, Herrmann M, Globinska A, Jansen K, Straumann A, Kubo T, Verschoor D, Wirz O, Castro-Giner F, Tan G, Rückert B, Ochsner U, Akdis M. A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. *Sci Adv* 2020; 6:eaaz3559.

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

Sawatzki M, Stienen M, Straumann A, Meyenberger C, Öhlschlegel C, Binek J. Endoscopic treatment of paraesophageal abscess in eosinophilic esophagitis after chest trauma. *Gastrointest Endosc* 2011

Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Banský G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. *Inflamm Bowel Dis* 2010

Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. *Inflammatory bowel diseases* 2009

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)